Sign In
Buy PHRRF
$0.0431
-0.0015 (-3.36%)
At Close: Jul 31, 2026
PharmaTher Collaborates with Craft Health to Evaluate CraftMake(TM) GMP-Ready Pharmaceutical 3D Printing Platform for Personalized Peptides
08:00am, Wednesday, 29'th Jul 2026
Toronto, Ontario--(Newsfile Corp. - July 29, 2026) - PharmaTher Holdings Ltd. (CSE: PHRM) (OTCQB: PHRRF) ("PharmaTher" or the "Company"), a specialty pharmaceutical company focused on personalized med
New division will address the limitations of traditional peptide compounding through 3D printing and AI PharmaTher plans to connect patients, physicians and qualified pharmacies through an integrated
PharmaTher Enters into Collaboration Agreement for KetaMist(R) to Advance Needle-Free Ketamine Treatment Toward FDA Approval
08:00am, Tuesday, 21'st Jul 2026
Collaboration combines more than 9,000 KetaMist® patient treatments with PharmaTher's prior FDA-approved ketamine experience Pursuing an efficient FDA development pathway toward approval for treatmen
PharmaTher Updates Strategy on Personalized Medicines for Peptides and Psychedelics
08:00am, Wednesday, 15'th Jul 2026
Toronto, Ontario--(Newsfile Corp. - July 15, 2026) - PharmaTher Holdings Ltd. (CSE: PHRM) (OTCQB: PHRRF) ("PharmaTher" or the "Company"), a
PharmaTher Evolves Platform Strategy with MEDBOTX(TM) Robotic 3D Printing for Personalized Medicines
08:00am, Wednesday, 27'th May 2026
MEDBOTX™ represents the evolution into a broader point-of-care manufacturing platform designed for personalized medicines, peptides and advanced dose formats Potential U.S. peptide reclassification
PharmaTher's Sairiyo Therapeutics to Explore PD-001, Its Patented Reformulated Cepharanthine, for Hantavirus
10:11am, Wednesday, 13'th May 2026
Independent research identified cepharanthine as a potential Hantavirus entry inhibitor, supporting further evaluation of Sairiyo's patented, orally bioavailable PD-001 cepharanthine formulation for H
PharmaDrug Sairiyo Therapeutics to Explore PD-001, Its Patented Reformulated Cepharanthine, for Hantavirus
08:50am, Wednesday, 13'th May 2026
Independent research identified cepharanthine as a potential Hantavirus entry inhibitor, supporting evaluation of Sairiyo's patented, orally bioavailable PD-001 formulation of cepharanthine for Hantav
Company believes supportive U.S. policy momentum may strengthen the strategic value of its ketamine patch, KetaVault™ platform, retained ketamine programs, and prior FDA-approved ketamine ANDA trans
PharmaTher's Microneedle Patch Platforms Positioned to Benefit from Major U.S. Catalysts in Psychedelics and Peptides
08:00am, Monday, 20'th Apr 2026
U.S. regulatory momentum in psychedelics and peptides could open new commercial opportunities for PharmaTher's PatchPrint™ automated manufacturing platform and PharmaPatch™ product platform as an
Anticipated peptide reclassification could expand the addressable market for PharmaTher's PharmaPatch™ product strategy and PatchPrint™ manufacturing platform, strengthening its position in next-g
PharmaTher Announces Filing of U.S. Patent Application for its Peptide Microneedle Patch Technology
08:00am, Monday, 13'th Apr 2026
Patent filing intended to strengthen PharmaTher's peptide formulation capabilities for PharmaPatch™ while complementing PatchPrint™ as part of the Company's broader microneedle patch development a
PharmaTher Introduces PatchPrint(TM) With Provisional Patent Filing and Commercialization Strategy for Microneedle Patches
08:00am, Thursday, 26'th Mar 2026
Leveraging its PharmaPatch™ experience, the Company is introducing PatchPrint™ to support existing microneedle patch programs and expand into on-demand personalized patch solutions, including pept
PharmaTher Expands PharmaPatch Delivery Platform into Therapeutic Peptides for the U.S. Market
08:00am, Tuesday, 03'rd Mar 2026
Toronto, Ontario--(Newsfile Corp. - March 3, 2026) - PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) (the "Company" or "PharmaTher"), a specialty pharmaceutical company focused on unlocking the
Toronto, Ontario--(Newsfile Corp. - February 2, 2026) - PharmaTher Holdings Ltd. (CSE: PHRM) (OTCQB: PHRRF) (the "Company" or "PharmaTher"), a specialty pharmaceutical company, today announced a new s
PharmaTher Expands PharmaPatch(TM) Platform into GLP-1 for Obesity, Leveraging Its Ketamine and Psychedelic Patch Programs
08:00am, Wednesday, 14'th Jan 2026
Toronto, Ontario--(Newsfile Corp. - January 14, 2026) - PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) (the "Company" or "PharmaTher"), a specialty pharmaceutical company focused on unlocking t
